Saredutant is primarily investigated for its potential therapeutic applications in the field of mental health, particularly as an antidepressant and anxiolytic agent. It functions as a selective antagonist of the NK2 receptor, which is implicated in the regulation of emotional and stress responses. By blocking this receptor, it may help alleviate symptoms of anxiety and depression, offering a novel approach to managing these conditions. Research has also explored its role in treating irritable bowel syndrome (IBS), as NK2 receptors are involved in gut motility and visceral pain. While clinical trials have shown promise, further studies are needed to fully establish its efficacy and safety for widespread use.